





Designing multi-arm multi-stage clinical trials
using a risk-benefit criterion for treatment
selection
Thomas Jakia∗, Lisa V. Hampsona
Multi-arm clinical trials that compare several active treatments to a common control have been proposed as an
efficient means of making an informed decision about which of several treatments should be evaluated further in
a confirmatory study. Additional efficiency is gained by incorporating interim analyses and in particular, seamless
Phase II/III designs have been the focus of recent research. Common to much of this work is the constraint that
selection and formal testing should be based on a single efficacy endpoint, despite the fact that in practice, safety
considerations will often play a central role in determining selection decisions. Here we develop a multi-arm multi-
stage design for a trial with an efficacy and safety endpoint. The safety endpoint is explicitly considered in the
formulation of the problem, selection of experimental arm and hypothesis testing. The design extends group-
sequential ideas and considers the scenario where a minimal safety requirement is to be fulfilled and the treatment
yielding the best combined safety and efficacy trade-off satisfying this constraint is selected for further testing. The
treatment with the best trade-off is selected at the first interim analysis while the whole trial is allowed to comprise
of J analyses. We show that the design controls the familywise error rate in the strong sense and illustrate the
method through an example and simulation. We find that the design is robust to misspecification of the correlation
between the endpoints and requires similar numbers of subjects to a trial based on efficacy alone for moderately
correlated endpoints. Copyright c© 2015 John Wiley & Sons, Ltd.
Keywords: familywise error rate; multi-arm multi-stage (MAMS); multiple endpoints; safety; treatment
selection.
1. Introduction
Prior to undertaking a confirmatory Phase III clinical trial, there is often uncertainty about which treatment should
be selected for evaluation from a number of candidates. Here, treatments could be different doses of the same drug
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or different combinations of multiple drugs. Uncertainty about which treatment to select often stems from the fact
that early phase trials typically evaluate medicines in different populations, using different endpoints, to those that
will be the focus of confirmatory studies. The current high failure rate of Phase III trials of around 50% [1] combined
with their substantial cost [2] make selecting an appropriate treatment for evaluation in Phase III of paramount importance.
As an efficient solution to this problem, designs for seamless Phase II/III multi-arm clinical trials have been proposed
which compare several active treatments with a common control group. Phase II of the study is used to learn about
all treatments. At the end of this first stage, one or more of the active treatments is selected and taken forward with
control for evaluation in Phase III. Data accumulated across both stages of the trial are used to test whether the selected
treatment(s) is (are) superior to control at the end of the study. The simultaneous comparison of several treatments means
that expected sample sizes and durations of multi-arm trials are markedly smaller than the alternative of evaluating each
treatment separately. For added efficiency, solutions that incorporate a series of interim analyses to allow early stopping
either for efficacy or to drop ineffective treatments have recently received attention [3–7]. The approaches discussed
in the literature to date can be characterized by two main differences. The first is the underlying statistical framework
which either generalizes group sequential designs [8, 9] to accommodate multiple treatment arms [3], or makes use of
p-value combination rules within closed testing procedures [10]. The second difference is the way in which treatments are
selected. In [3], for example, only the best performing treatment is selected at the first interim analysis and subsequently
compared to control over multiple stages, while in [6] all treatments surpassing a threshold at each stage are continued.
Meanwhile, [11] advocate a rule that selects all treatments close to the best performing treatment at the first interim
analysis.
A further commonality of several of the approaches discussed in the literature is the assumption of normally distributed
data and the fact that a single endpoint is considered. However, there are exceptions. For results for non-normal endpoints
see, for example, [12–14]. More generally, adaptive procedures using p-value combination rules within closed testing
procedures make no assumptions about the distribution of patient responses nor place any constraints on the form of
the treatment selection rule: the only constraint is that p-values for testing elementary and intersection null hypotheses
must follow a Uniform(0,1) (or stochastically larger) distribution under the null [5]. For procedures which consider more
than endpoint see [15] which describes a seamless Phase II/III trial using a composite rule based on two hierarchically
ordered efficacy endpoints to guide treatment selection decisions, as well as relevant safety data; to adjust for multiple
testing, pairwise comparisons of selected treatments against placebo are adjusted using a Bonferroni correction. Early
phase oncology trials also often assess efficacy and monitor toxicity; see [16] for a Phase I/II trial design combining
time-to-response and time-to-toxicity endpoints into a single statistic used for interim decision making, weighting pairs of
outcomes according to utilities elicited from experts. In other areas, such as mental health, co-primary efficacy endpoints
are measured and no single measure is accepted as definitive. Although it is sometimes sensible to combine different
endpoints into a single test statistic, substantial gains in efficiency can be achieved if they are evaluated jointly, especially
when endpoints capture the effects of a treatment on different aspects of the disease. Furthermore, combining information
obtained on efficacy and safety endpoints into a single test statistic will be inappropriate since good efficacy will not
compensate for poor safety in practice.
Methods for two-arm group-sequential trials with multivariate normal endpoints [17, 18], two binary endpoints [19],
and a mixture of time-to-event and nonfailure endpoints [20] have been developed. In this article, we develop a multi-arm
multi-stage (MAMS) design for a trial with an efficacy endpoint and a safety endpoint. The novelty of the proposed design
is that it is based on a joint model for the efficacy and safety outcomes while information on both endpoints is incorporated
into treatment selection decisions. We consider the situation where a minimal safety requirement is to be fulfilled and the
treatment with the best combined safety and efficacy trade-off satisfying this constraint is selected for further testing.
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Selection is made at the first interim analysis while the whole trial is allowed to comprise of J analyses. Final decisions
about a selected treatment are based on tests of efficacy and safety relative to control. In Section 2 we show that the
design controls the familywise error rate (FWER) in the strong sense and discuss methods for sample size calculations. In
Section 3, we illustrate the method through an example and simulations based on the TAILoR study, a multi-arm trial of
treatments to reduce insulin resistance in HIV-positive patients. We conclude in Section 4 with a discussion of our findings
and avenues for future research.
2. Statistical framework
We propose MAMS designs which begin in Stage 1 by comparing K active treatments with a common control group. The
overall objective of the trial is to select the “best” of the K treatments and then make comparisons with control. Rather
than be based solely on efficacy, treatment selection decisions will often reflect a compromise between the potential
benefits and side effects of a new therapy. For example, a new treatment may need to demonstrate non-inferior safety
and superior efficacy to represent a clinically meaningful advantage over a well-understood control. We propose designs
which explicitly account for the impact of safety considerations on decision making. Throughout we restrict attention to
the case where a single treatment is selected at the first analysis. We begin by focusing attention on a single stage design
and discuss the natural extension to multiple stages in Section 2.4.
2.1. Treatment selection rules
Suppose the trial proceeds in Stage 1 by measuring a bivariate endpoint on each patient. Labelling control as treatment

















, i = 1, . . . , n; k = 0, 1, . . . ,K,
where ρ is the within-subject correlation, and we assume that the variance-covariance matrix of responses is known.
Let θEk = µEk − µE0 and θSk = µSk − µS0 measure the advantage of treatment k over control for efficacy and safety,
respectively, where we will assume that increases in response are desirable for both endpoints. Thus, θ = (θE ,θS) is
a vector of length 2K containing the efficacy and safety effects of the K treatments. For each treatment k = 1, . . . ,K,
we define two hypotheses HEk : θEk ≤ 0 and HSk : θSk ≤ 0. The null hypothesis we wish to test is H0k : HEk ∪HSk
stating that treatment k is either ineffective or unsafe in comparison with control; rejecting H0k implies that treatment
k is both effective and safe. The global null hypothesis H0 :
⋂K
k=1H0k represents the case that all K treatments are
either unsafe or ineffective. For ease of presentation, we consider tests of superiority although [18] observe that it is
straightforward to accommodate tests of non-inferiority in this framework by subtracting the non-inferiority margin (for
a difference in means) from patient responses on the control treatment.
For presentational purposes, we assume a common 1 : 1 allocation of patients to each of the K active treatments and
control, and denote the number of patient responses available on each arm by n. Thus, at the end of Stage 1, for each
k = 1, . . . ,K, Fisher’s information for θTk takes a common value denoted by IT = n/(2σ2T ), for T ∈ E,S. In Appendix
A.1 of the Supplementary Materials, we outline how the procedure could be extended to accommodate a common r : 1
allocation of patients to active treatments and control. Define µˆTk as the maximum likelihood estimator (MLE) of µTk.
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Only treatments meeting a pre-specified minimum safety requirement may be considered for selection. Let NS denote
the number of treatments eligible for selection which are indexed by the selection set SS = {k : ZSk > c}. If NS = 0,







where wE and wS are pre-specified non-negative weights satisfying w2E + w
2
S = 1. Unplanned deviations from the
pre-specified treatment selection rule could lead to inflation of the FWER above the nominal level. One of the motivations
of this design is, however, to formally include safety in the decision making so that such deviations become less
frequent. Should unexpected modification be necessary, however, conditional error principle [21] can be used to maintain
FWER control. It is worth pointing out that we incorporate the safety threshold because the objective function allows
good efficacy to compensate for poor safety. In practice this would only be acceptable up to a certain point which is
defined by the safety threshold. A natural choice for this threshold in our opinion is c = 0, that is, we only select from
treatments with comparable or better safety than control in stage 1 although in principle other values could be used instead.
Let i? index the treatment selected from Stage 1 on the basis of the objective function Oi? = maxk∈SS{Ok}. Since the
selected treatment will only be declared preferable to control if we can reject the null hypothesis H0i? : HEi? ∪HSi? ,
a natural choice of weights is wE = wS =
√
0.5 as this ensures consistency between selection decisions and the final
analysis of the trial.
We propose single stage tests of H01, . . . ,H0K with stopping rules of the form:
If ZS1, . . . , ZSK ≤ c Stop and accept H0
Otherwise Select from SS treatment i? maximising objective function O
and conduct the final analysis.
At the final analysis:
If ZEi? ≥ uE and ZSi? ≥ uS Stop and reject H0 in favour of H1i? : {θEi? > 0} ∩ {θSi? > 0},
Otherwise Stop and accept H0.
(3)
At the final analysis of the proposed test, superiority can only be claimed for the selected treatment i?. Consequently,
we define the FWER of the procedure as P{Reject H0 in favour of a false H1i? ; θ}. This probability depends on
both the minimum safety requirement, c, and the stopping boundaries (uE , uS). Our approach is to fix c = 0 and
find the pair of critical values maintaining strong control of the FWER at level α. This criterion stipulates that
P{Reject H0 in favour of a false H1i? ; θ} ≤ α for all configurations of θ with at least one θTk ≤ 0, for T ∈ {E,S} and
k ∈ {1, . . . ,K}. If H01, . . . ,H0K are all true, a familywise error is made if the test terminates with rejection of H0i?
whatever treatment is selected, and the FWER is given by P{ZEi? ≥ uE , ZSi? ≥ uS , NS ≥ 1; θ}. In the remainder of this
section, we discuss how to find (uS , uE) maintaining strong control of the FWER.
2.2. Specification of test boundaries
We propose choosing the boundaries of test (3) to ensure the FWER is controlled at level α as we approach the
following two “worst-case” limiting configurations of θ: 1) θE = (∞, . . . ,∞), θS = (0, . . . , 0); and 2) θE = (0, . . . , 0),
θS = (∞, . . . ,∞). We claim that specifying test boundaries according to this criterion ensures strong control of the
FWER, and prove this claim using a combination of analytical arguments and simulation. This result agrees with the
findings of [18] for the case that K = 1. Let Γ represent a set indexing treatments with positive efficacy and safety effects.
We begin considering a subset of the null parameter space comprising configurations of θ such that
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(a) For all treatments k with k /∈ Γ, θEk ≤ 0 and θSk ≤ 0; or
(b) For all treatments k with k /∈ Γ, θEk ≥ 0 and θSk ≤ 0; or
(c) For all treatments k with k /∈ Γ, θEk ≤ 0 and θSk ≥ 0.
Under the global null hypothesis, Γ = ∅, and the constraints on θ configurations defined above correspond to assuming
that effects of different treatments on the same endpoint have the same sign. We claim that the FWER of procedure (3)
under configurations of θ in this restricted global null parameter space is maximised under constellations with
θE = (γE , . . . , γE) and θS = (γS , . . . , γS), and furthermore that local maxima of the FWER are attained in the limit as
γS →∞ and γE = 0, and in the limit as γE →∞ and γS = 0.
To prove these claims, we begin by assuming that all treatments are always eligible for selection and consider the
configuration of θ with θE = (γE , . . . , γE) and θS = (γS , . . . , γS). Then, letting some elements of θS fall below
γS decreases stochastically the distribution of (ZEi? , ZSi?) as both statistics tend to take lower values on average.
To explain this, note that since all treatments remain competitive for efficacy, treatments must perform well for ZS
if they are to rank highly for the objective function O. Thus, selection decisions are, in effect, driven primarily by
safety data so that a treatment may beat its competitors on the basis of O with lower values of ZE . Letting some
of the θSks drop below γS also decreases stochastically the distribution of ZSi? too: the treatment associated with
the largest element of θS is now ‘safest’ by some margin, meaning that on average, lower values of ZS will be
sufficient for it to beat the weaker competition to ensure selection. Similar arguments imply keeping θS fixed at γS
and letting some elements of θE fall below γE decreases stochastically the distributions of ZEi? and ZSi? . On the
other hand, simultaneously forcing elements of θE below γE and elements of θS below γS decreases stochastically the
distribution of (ZEi? , ZSi?): systematic differences between treatments imply that it is possible for a good safety profile
to compensate for poor efficacy (and vice-versa) resulting in lower average values of ZE and ZS for the selected treatment.
Letting θE = (γE , . . . , γE) and θS = (γS , . . . , γS), increasing γE or γS increases the probability of rejecting H0. Thus,
looking across the restricted global null parameter space, the probability of making a familywise error is maximised at the
boundaries of the space, that is, in the limit as γS →∞ and γE = 0, and in the limit as γE →∞ and γS = 0. If for some
treatment k, θEk and θSk are both positive so that Γ 6= ∅, this treatment will be more likely to be selected, in which case
we cannot commit a familywise error and the FWER decreases. Therefore, controlling the FWER for all configurations
of θ in the restricted global null parameter space ensures the FWER is controlled over the wider null parameter space
defined above.
So far we have consider the case that all treatments are always eligible for selection, in effect setting c = −∞. However,
we claim that for general values of c, local maxima of the FWER are attained in the limit as we approach the worst case
configurations of θ identified above. This is because under this requirement, the expected size of SS is determined by
γS . Therefore, increasing γS increases stochastically the distribution of (ZEi? , ZSi?) as the average number of treatments
from which we can select increases. In particular, as γS approaches ∞, SS includes all K treatments almost surely and
rejects H0 if ZEi? > uE . The probability of falsely rejecting H0 is then maximised for γE = 0. Similarly, setting γS = 0,
the FWER reaches a second local maximum as γE →∞. To see this note that for γS = 0, inclusion of treatments in the
selection set is random so that the probability of rejection is maximised for maximal effect on efficacy.
To complete our justification for designing test (3) to control the FWER under the“worst-case” limiting configurations
of θ, we go beyond the arguments stated above to claim that this approach ensures strong control of the FWER. In
particular, tests defined in this way will control the FWER for any configuration of θ with θE = (θE1, . . . , θEK) and
θS = (θS1, . . . , θSK), where one θ·i is zero and the other∞. While we cannot prove these claims analytically, we evaluate
them via simulation in Section 3.2. Assuming for now that these claims do hold, it is appropriate to choose boundaries
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(uE , uS) to ensure that
lim
γS→∞
P{ZEi? ≥ uE , ZSi? ≥ uS | NS ≥ 1;θE = (0, . . . , 0),θS = (γS , . . . , γS)} = α, (4)
lim
γE→∞
P{ZEi? ≥ uE , ZSi? ≥ uS | NS ≥ 1;θE = (γE , . . . , γE),θS = 0} = α/P{NS ≥ 1;θS = 0}, (5)
since limγS→∞ P{NS ≥ 1;θS = (γS , . . . , γS)} = 1 and the probability that at least one treatment meets the minimum
safety criterion does not depend on θE . As γS and γE approach∞, the bivariate probabilities on the LHSs of (4) and (5)
converge to univariate probabilities. We find (uE , uS) so that the limits of these marginal rejection probabilities are equal
to the values required to ensure FWER control. Limits of rejection probabilities are found by integrating the limits of the
marginal conditional densities of ZEi? and ZSi? derived in Appendix A.2 of the Supplementary Materials. It is important
to note that these marginal densities depend on the correlation coefficient ρ. So far we have assumed that this parameter
is known. In Section 3.3 we explore the robustness of attained FWERs to misspecification of ρ. Marginal densities of test
statistics depend on variances only through the information levels IE and IS . The effect of assuming a known variance
has previously been investigated in similar settings [22] and the quantile substitution approach described in [8] has been
shown to work well.
2.3. Sample size calculations
We wish to calculate the sample size needed for test (3) to attain a disjunctive power, that is, probability of rejecting at least
one false null hypothesis [5, 23], of 1− β under the configuration of θ with θE = (δ0, . . . , δ0, δ) and θS = (γS , . . . , γS)
with γS > 0. We may approximate further by letting γS →∞, which can be justified by the belief that a potentially unsafe
treatment is unlikely to be included in the trial. In this case, a test’s power simplifies to
lim
γS→∞
P{ZEi? ≥ uE , ZSi? ≥ uS | NS ≥ 1;θE = (δ0, . . . , δ0, δ),θS = (γS , . . . , γS)}
= lim
γS→∞
P{ZEi? ≥ uE | NS ≥ 1;θE = (δ0, . . . , δ0, δ),θS = (γS , . . . , γS)}, (6)
and limiting probabilities are found by integrating the limits of the marginal conditional density of ZEi? . Using the results
of Appendix A.1 and following the workings of Appendix A.2.1 of the Supplementary Materials, we can show that limiting
































dx1 dy dm, (7)




√ISwE(x1 − IEδ0) and
√
(IEIS)`5 =
√IEwSy +√ISwE(x1 − IEδ). For computational convenience, we proceed assuming that IE = IS = I1 and conduct a one-
dimensional search to find the common information level I?1 for which rejection probability (7) equals 1− β; at each
iteration of this search, boundaries for monitoring score statistics ZEi? and ZSi? are updated to ensure strong control
of the FWER at level α under the proposed information level. Since information level I?1 typically corresponds to
requiring fractions of subjects, in practice we propose rounding up the total sample size to n? = 2 max{σ2EI?1 , σ2SI?1}
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patients per treatment arm. The test is then applied with critical values calculated for information levels IE = n?/(2σ2E)
and IS = n?/(2σ2S). If a procedure’s power is monotone increasing in IE and IS , this sample size criterion will be
conservative in the sense that attained power will exceed 1− β. In Section 3.2 we use simulation to evaluate properties of
tests designed according to the proposed sample size criterion.
2.4. Beyond single stage designs
It is straightforward to extend our approach to find designs maintaining control of the FWER when multiple interim
analyses are planned. Let ZTk,j denote the score statistic at interim analysis j for endpoint T on treatment k. A multistage
test of H01, . . . ,H0K has a stopping rule of the form:
At the end of stage 1:
If ZS1,1, . . . , ZSK,1 ≤ c Stop and accept H0
Otherwise Select from SS treatment i? maximising objective function O
and conduct interim analysis 1.
At interim analysis j = 1, . . . , J :
If ZEi?,j ≥ uEj and ZSi? ≥ uSj Stop and reject H0 in favour of H1i? : {θEi? > 0} ∩ {θSi? > 0},
If ZEi?,j ≤ lEj or ZSi?,j ≤ lSj Stop and accept H0,
Otherwise Continue to interim analysis j + 1.
(8)
Multi-stage tests are defined with binding futility rules so that if either ZEi?,j ≤ lEj or ZSi?,j ≤ lSj the procedure must
stop immediately at interim analysis j without declaring treatment i? safe and effective. Criteria (4)-(5) imply that we
can uncouple the searches needed to find critical values for monitoring efficacy and safety score statistics. Furthermore,
for T ∈ {E,S}, increments ZTi?,2 − ZTi?,1, . . . , ZTi?,J − ZTi?,J−1 are independent and follow the same distribution as
increments in score statistics generated by a univariate group sequential test (GST) without selection [3]. Thus, we can
find (lE1, uE1), . . . , (lEJ , uEJ) as the boundaries defining a one-sided univariate GST monitoring {ZEi?,1, . . . , ZEi?,J}
with limiting conditional type I error rate α given NS ≥ 1 under γE = 0 and letting gammaS →∞. Following [3], we




P{ZEi?,1 ∈ (lE1, uE1), . . . , ZEi?,j−1 ∈ (lE(j−1), uE(j−1)), ZEi?,j ≥ uEj | NS ≥ 1;θE = 0,θS = (γS , . . . , γS)}
= fU (tj)− fU (tj−1)
lim
γS→∞
P{ZEi?,1 ∈ (lE1, uE1), . . . , ZEi?,j−1 ∈ (lE(j−1), uE(j−1)), ZEi?,j ≤ lEj | NS ≥ 1;θE = 0,θS = (γS , . . . , γS)}
= fL(tj)− fL(tj−1),
where tj is the fraction of IEJ , the maximum information level for the efficacy treatment effect, accumulated by
stage j, and fU and fL are monotone increasing functions satisfying fU (0) = fL(0) = 0 and, for t ≥ 1, fU (t) = α
and fL(t) = 1− α. A similar process can be used to find the boundaries (lS1, uS1), . . . , (lSJ , uSJ) for monitoring
{ZSi?,1, . . . , ZSi?,J}. Safety boundaries are determined using fL and fU to spend error probabilities as a function of
the observed information for θE,i? ; this ensures that uEJ = lEJ and uSJ = lSJ , so that procedure (8) terminates properly
at analysis J with a final hypothesis decision for any choice of IEJ even when the variances of the efficacy and safety
endpoints differ. To find the required sample size, we follow Section 2.3 and search for the maximum information level
IEJ for which the test has power 1− β according to criterion (6) under an anticipated information sequence IE1, . . . , IEJ ,
setting each ISj = σ2EIEj/σ2S to account for differences between the rates at which information on safety and efficacy
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effects accumulate. The test will recruit up to n? = 2σ2EIEJ patients on the selected treatment and control in the absence
of early stopping.
3. Example
In this section we will examine the operating characteristics of the proposed designs through a series of examples
motivated by the TAILoR study, a MAMS trial comparing several doses of telmisartan with control for the reduction of
insulin resistance in HIV-positive patients receiving combination antiretroviral therapy [6]. The study, which is currently
ongoing, uses the change in the HOMA-IR index between baseline and 24 weeks as the efficacy endpoint.
In this section we imagine how the TAILoR study might have been designed as a single stage procedure of the form
shown in (3), using the methodology described in this paper to incorporate a safety endpoint in addition to the efficacy
endpoint used in the ongoing study. A plausible safety endpoint is change in systolic blood pressure from baseline
since telmisartan is licensed for the treatment of hypertension. An excessive drop in blood pressure for patients without
hypertension would be considered an undesirable safety risk. With the exception of this modification, we will assume the
design parameters of the original TAILoR study. We therefore stipulate a FWER of 0.05 and seek designs randomising
patients equally across treatment arms with power 0.9 to correctly reject one false null hypothesis. When the TAILoR study
was first designed, four doses of telmisartan were planned. For consistency with previous publications [22,25] we consider
the scenario thatK = 4 active treatments are to be compared with control, despite the ongoing study using three doses due
to last minute changes to the study. The standardized desirable effect for efficacy, δ, used for sample size calculations is
set as 0.545 and the minimum clinically important difference is defined as 0.178. Under the assumption that all treatments
are truly safe, we do not require specification of an effect on safety when using (7) for sample size calculations. However,
if such an assumption is undesirable, Equation (6) in Appendix A.1 of the Supplementary Materials can be used with the
anticipated safety effect. Boundary calculations and sample size determinations require us to numerically evaluate multi-
dimensional integrals. For this purpose we used the R package cubature [26] and verified solutions for the obtained
boundaries using 100,000 fold simulations.
3.1. Design options
Figure 1 shows how the required information per arm and safety / efficacy stopping boundaries vary as the weight wE
changes. The within-subject correlation of efficacy and safety responses is assumed to be 0.4.The information required is
largest when selection of the treatment is based only on the safety endpoint (wE = 0) while it decreases as the weight on
efficacy increases. Similarly, both the efficacy and safety boundaries decrease as the required information decreases, as
expected. There is, however, an apparent difference between the efficacy and safety boundary, depending on the weight
given to each endpoint. For small weights on efficacy, the efficacy boundary is smaller than the safety boundary, while this
pattern reverses once more weight is attributed to efficacy for selection. For equal weights, the boundaries for efficacy and
safety are identical.
3.2. Error rates
In this section we illustrate properties of tests of the form (3) designed and conducted with equal weights wE = wS and
correlation coefficient ρ = 0.4. Under this setting the information required per arm is I?1 = 47.148 (n = 94.296) and the
stopping boundaries are uE = uS = 14.466. Empirical error rates based on 10,000 simulation runs for each point on a grid
of parameters are shown in Figure 2 for cases where all treatments have the same pair of effects (γE , γS) versus control.
The left hand panel clearly shows that the FWER of the design is maximised if one of the effects is at the boundary
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Figure 1. Information per arm, I?1 (left), and safety/efficacy stopping boundary (right) needed for tests of the form (3) to maintain strong control of the FWER at level 0.05 and
attain limiting power 0.9 when θE = (0.178, 0.178, 0.178, 0.545) and all treatments are safe. Designs are found for tests making treatment selection decisions according to


































Figure 2. Empirical FWERs over the null space (left) and power to correctly reject at least one false null hypothesis (right) of tests of the form (3) designed to maintain strong
control of the FWER at level 0.05 and to attain power 0.9 under θE = (0.178, 0.178, 0.178, 0.545) (when all treatments are safe). Tests are designed and conducted with
K = 4, w2E = w
2
S = 0.5, ρ = 0.4 and σE = σS = 1. FWER and power is evaluated under configurations of θ with θS = (γS , . . . , γS) and θE = (γE , . . . , γE).
Results are based on 10,000 simulations for each parameter configuration.
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Figure 3 provides empirical FWERs for parameter configurations of the from θE = (θE1, . . . , θEK), θS =
(θS1, . . . , θSK), where one parameter of each pair (θEi, θSi) is large and the other zero to evaluate the conjecture
made in Section 2.2 that designs will control these at the nominal level α. For the purpose of this evaluation, the large
effect was set to 1 million and 100,000 fold simulations are used. From the graph it can be seen that the FWER is well
controlled for any parameter configuration, as conjectured.

























Figure 3. Empirical FWER for different configurations of the true effects for tests of the form (3) designed to maintain strong control of the FWER at level 0.05. Tests are designed
and conducted withK = 4, ρ = 0.4,w2E = w
2
S = 0.5 and σE = σS = 1. Results are based on 100,000 simulations for each parameter configuration. The dashed horizontal
line corresponds to the nominal FWER and the dotted line to the upper bound for simulation error.
Figure 4 shows how the power of the procedure changes as the safety of the experimental treatments change. Results
are presented for one to four treatments exhibiting the desired effect for efficacy of 0.545 while the remaining have the
minimum clinically important effect of 0.178. Power increases as the safety of the treatments increases and reaches the
desired level of 0.9 for a safety effect of around 0.5. Power also increases as the number of treatments with the desired
efficacy increases, although this increase diminishes somewhat with the number of efficacious treatments.
3.3. Misspecification of ρ
When specifying our model we have so far assumed that response variances and their correlation are known. In this
section, we will investigate the robustness of our design to the assumption of known correlation. Figure 5 shows the
simulated FWER based on 100,000 simulations of tests as the correlation between endpoints varies. Six different true
parameter constellations are considered, namely the global null hypothesis and five “worst case” configurations (once
again using 1 million instead of infinity for simulation purposes). For all six settings, the FWER is controlled at the design
value ρ = 0.4 and the procedure is conservative for all correlations below this. Under the global null hypothesis, only
perfect correlation results in an inflation of the FWER while it is inflated once the true correlation is above the design
value for the worst case configurations. The maximum inflation, achieved under perfect positive correlation, is, however,
small at 10% of the nominal value of the FWER.
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Figure 4. Empirical power to correctly reject at least one false null hypothesis of tests of the form (3) designed to maintain strong control of the FWER at level 0.05 and
attain power 0.9 under θE = (0.178, 0.178, 0.178, 0.545) (when all treatments are safe). Tests are designed and conducted with K = 4, w2E = w
2
S = 0.5, ρ = 0.4 and
σE = σS = 1. Power is evaluated under configurations of θ with θS = (γS , . . . , γS) and θE = (δ0, . . . , δ0, δ, . . . , δ) such that j treatments have the desired effect for
efficacy (δ = 0.545) and the remaining have the minimum clinically important effect (δ0 = 0.178). Results are based on 100,000 simulations for each parameter configuration.



































Figure 5. Empirical FWERs of tests of the form (3) designed to maintain strong control of the FWER at level 0.05 and attain power 0.9 under θE =
(0.178, 0.178, 0.178, 0.545) (when all treatments are safe). Tests are designed and conducted with K = 4, w2E = w
2
S = 0.5 and σE = σS = 1. Tests are also
designed assuming ρ = 0.4 but conducted for a range of correlations. Empirical error probabilities are evaluated under configurations of θ with θS = (γS , . . . , γS) and
θE = (γE , . . . , γE). Results are based on 100,000 simulations for each scenario.
Tamhane et al. [27] observe that typically either the correlation is assumed to be known (as done here) or a correlation
of one is treated as the worst case scenario. Given the relative conservatism of the proposed procedure at reasonable
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values of the parameters, we believe the former is sufficient, although the latter would certainly also be possible. A more
elegant solution given in [27] overcomes this problem by estimating the correlation mid-study, and uses an approach due
to Berger & Boos [28] to obtain an upper bound for the FWER accounting for the sampling error of the sample correlation
coefficient
4. Discussion
In this paper we have presented an approach for designing MAMS studies based on a joint model for efficacy and
safety data which considers both endpoints when selecting the most promising treatment for further investigation
and tests the efficacy and safety of the selected treatment relative to control. The main challenge with obtaining the
relevant distributions of the test statistics arose from the requirement to select from treatments satisfying a minimum
safety requirement. We have shown that the FWER is strongly controlled under the assumption that effects of different
treatments for the same endpoint have the same sign. Our simulation results show, however, that strong control of the
FWER also appears to hold when this assumption is not made.
In the presentation and derivations we have made a number of assumptions that may not be appropriate for specific
settings. For example, single-stage designs are formulated assuming patient responses follow a bivariate normal
distribution with a common correlation between efficacy and safety responses across the active and control treatments.
In addition, calculations assume that at the end of Stage 1 there is a common information level for θE,1, . . . , θE,K and
a common information level for θS,1, . . . , θS,K . This joint distribution will not in general apply if data do not follow a
normal distribution since information levels and correlation coefficients may depend on unknown parameters, such as
response rates in the case of binary data (see Section 9 of [27]). One potential solution would be to approximate and
derive test boundaries setting the correlation coefficient and information levels to the values that would apply under
θE = θS = 0. However, further simulations would be needed to verify whether this approach would maintain strong
control of the FWER at a level close to the nominal value.
Another simplifying assumption we have made is to propose designs setting the safety threshold to be zero, so that only
treatments with better safety than control can be selected. A simple shift of the safety test statistic can be used to allow
for different thresholds to be used. Similarly, it may be desirable to select treatments only based on efficacy provided that
the treatment is safe enough. Simply setting the weight on safety within the objective function to zero can accomodate
this situation. Finally, as outlined before, it may not be appropriate to test for superiority in terms of safety over control.
Shifting the respective test statistics for safety will allow non-inferiority hypothesis to be used instead. It is also easy
to envisage application of this design in other settings, such as mental health trials, where there are co-primary efficacy
endpoints. In these cases, no minimal threshold would be applied to either efficacy endpoint − the ideas of this work
apply to this, somewhat simpler, situation setting the threshold c = −∞.
One great benefit of multi-stage clinical trials is their reduced expected sample size compared with single stage
designs. Such gains can, however, only be realized, if the primary endpoint is observed quickly relative to the recruitment
time [29]. When this is not the case, it would be of interest to investigate whether methods such as the one described
in [30] can be extended to make selection decisions based on intermediate endpoints in the setting discussed in this paper.
Another area for further work regards how to calculate confidence intervals on termination of tests of the form (3).
The procedure based around hypothesis testing described here allows almost formulaic decisions about the superiority of
experimental treatments over control. It is essential, however, that confidence intervals should also be available to inform
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decision makers about the probable sizes of any efficacy and safety benefits, in order to give a complete description of the
evidence supporting a selected treatment. Future work will be necessary to evaluate if related work [14,31] can be utilized
to obtain interval estimates as well.
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